Global Multi-ingredient Codeine Market Growth 2025-2031

Publication ID:

LPI02254071

Publication Date:

February 27, 2025

Pages:

118

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Multi-ingredient Codeine market size is predicted to grow from US$ 223 million in 2025 to US$ 322 million in 2031; it is expected to grow at a CAGR of 6.3% from 2025 to 2031.
Multi-ingredient Codeine means the drugs contain codeine and another ingredient.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淢ulti-ingredient Codeine Industry Forecast鈥� looks at past sales and reviews total world Multi-ingredient Codeine sales in 2024, providing a comprehensive analysis by region and market sector of projected Multi-ingredient Codeine sales for 2025 through 2031. With Multi-ingredient Codeine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Multi-ingredient Codeine industry.
This Insight Report provides a comprehensive analysis of the global Multi-ingredient Codeine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Multi-ingredient Codeine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Multi-ingredient Codeine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Multi-ingredient Codeine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Multi-ingredient Codeine.
This report presents a comprehensive overview, market shares, and growth opportunities of Multi-ingredient Codeine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
15mg
30mg
60mg
Segmentation by Application:
Narcotic Analgesic
Antitussive
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Taiji
Mallinckrodt
TEVA
Johnson & Johnson
Medreich
Sanofi Aventis
Cipla
Hikma
Pharmaceutical Associates
Novartis
Apotex
Mylan
Aristo Pharma GmbH
Lannett Company
Laboratoire Riva
Key Questions Addressed in this Report
What is the 10-year outlook for the global Multi-ingredient Codeine market?
What factors are driving Multi-ingredient Codeine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Multi-ingredient Codeine market opportunities vary by end market size?
How does Multi-ingredient Codeine break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Multi-ingredient Codeine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Multi-ingredient Codeine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Multi-ingredient Codeine by Country/Region, 2020, 2024 & 2031
2.2 Multi-ingredient Codeine Segment by Type
2.2.1 15mg
2.2.2 30mg
2.2.3 60mg
2.3 Multi-ingredient Codeine Sales by Type
2.3.1 Global Multi-ingredient Codeine Sales Market Share by Type (2020-2025)
2.3.2 Global Multi-ingredient Codeine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Multi-ingredient Codeine Sale Price by Type (2020-2025)
2.4 Multi-ingredient Codeine Segment by Application
2.4.1 Narcotic Analgesic
2.4.2 Antitussive
2.4.3 Others
2.5 Multi-ingredient Codeine Sales by Application
2.5.1 Global Multi-ingredient Codeine Sale Market Share by Application (2020-2025)
2.5.2 Global Multi-ingredient Codeine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Multi-ingredient Codeine Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Multi-ingredient Codeine Breakdown Data by Company
3.1.1 Global Multi-ingredient Codeine Annual Sales by Company (2020-2025)
3.1.2 Global Multi-ingredient Codeine Sales Market Share by Company (2020-2025)
3.2 Global Multi-ingredient Codeine Annual Revenue by Company (2020-2025)
3.2.1 Global Multi-ingredient Codeine Revenue by Company (2020-2025)
3.2.2 Global Multi-ingredient Codeine Revenue Market Share by Company (2020-2025)
3.3 Global Multi-ingredient Codeine Sale Price by Company
3.4 Key Manufacturers Multi-ingredient Codeine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Multi-ingredient Codeine Product Location Distribution
3.4.2 Players Multi-ingredient Codeine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Multi-ingredient Codeine by Geographic Region
4.1 World Historic Multi-ingredient Codeine Market Size by Geographic Region (2020-2025)
4.1.1 Global Multi-ingredient Codeine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Multi-ingredient Codeine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Multi-ingredient Codeine Market Size by Country/Region (2020-2025)
4.2.1 Global Multi-ingredient Codeine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Multi-ingredient Codeine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Multi-ingredient Codeine Sales Growth
4.4 APAC Multi-ingredient Codeine Sales Growth
4.5 Europe Multi-ingredient Codeine Sales Growth
4.6 Middle East & Africa Multi-ingredient Codeine Sales Growth
5 Americas
5.1 Americas Multi-ingredient Codeine Sales by Country
5.1.1 Americas Multi-ingredient Codeine Sales by Country (2020-2025)
5.1.2 Americas Multi-ingredient Codeine Revenue by Country (2020-2025)
5.2 Americas Multi-ingredient Codeine Sales by Type (2020-2025)
5.3 Americas Multi-ingredient Codeine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Multi-ingredient Codeine Sales by Region
6.1.1 APAC Multi-ingredient Codeine Sales by Region (2020-2025)
6.1.2 APAC Multi-ingredient Codeine Revenue by Region (2020-2025)
6.2 APAC Multi-ingredient Codeine Sales by Type (2020-2025)
6.3 APAC Multi-ingredient Codeine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Multi-ingredient Codeine by Country
7.1.1 Europe Multi-ingredient Codeine Sales by Country (2020-2025)
7.1.2 Europe Multi-ingredient Codeine Revenue by Country (2020-2025)
7.2 Europe Multi-ingredient Codeine Sales by Type (2020-2025)
7.3 Europe Multi-ingredient Codeine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Multi-ingredient Codeine by Country
8.1.1 Middle East & Africa Multi-ingredient Codeine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Multi-ingredient Codeine Revenue by Country (2020-2025)
8.2 Middle East & Africa Multi-ingredient Codeine Sales by Type (2020-2025)
8.3 Middle East & Africa Multi-ingredient Codeine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multi-ingredient Codeine
10.3 Manufacturing Process Analysis of Multi-ingredient Codeine
10.4 Industry Chain Structure of Multi-ingredient Codeine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Multi-ingredient Codeine Distributors
11.3 Multi-ingredient Codeine Customer
12 World Forecast Review for Multi-ingredient Codeine by Geographic Region
12.1 Global Multi-ingredient Codeine Market Size Forecast by Region
12.1.1 Global Multi-ingredient Codeine Forecast by Region (2026-2031)
12.1.2 Global Multi-ingredient Codeine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Multi-ingredient Codeine Forecast by Type (2026-2031)
12.7 Global Multi-ingredient Codeine Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Taiji
13.1.1 Taiji Company Information
13.1.2 Taiji Multi-ingredient Codeine Product Portfolios and Specifications
13.1.3 Taiji Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Taiji Main Business Overview
13.1.5 Taiji Latest Developments
13.2 Mallinckrodt
13.2.1 Mallinckrodt Company Information
13.2.2 Mallinckrodt Multi-ingredient Codeine Product Portfolios and Specifications
13.2.3 Mallinckrodt Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Mallinckrodt Main Business Overview
13.2.5 Mallinckrodt Latest Developments
13.3 TEVA
13.3.1 TEVA Company Information
13.3.2 TEVA Multi-ingredient Codeine Product Portfolios and Specifications
13.3.3 TEVA Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 TEVA Main Business Overview
13.3.5 TEVA Latest Developments
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Information
13.4.2 Johnson & Johnson Multi-ingredient Codeine Product Portfolios and Specifications
13.4.3 Johnson & Johnson Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Johnson & Johnson Main Business Overview
13.4.5 Johnson & Johnson Latest Developments
13.5 Medreich
13.5.1 Medreich Company Information
13.5.2 Medreich Multi-ingredient Codeine Product Portfolios and Specifications
13.5.3 Medreich Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Medreich Main Business Overview
13.5.5 Medreich Latest Developments
13.6 Sanofi Aventis
13.6.1 Sanofi Aventis Company Information
13.6.2 Sanofi Aventis Multi-ingredient Codeine Product Portfolios and Specifications
13.6.3 Sanofi Aventis Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Sanofi Aventis Main Business Overview
13.6.5 Sanofi Aventis Latest Developments
13.7 Cipla
13.7.1 Cipla Company Information
13.7.2 Cipla Multi-ingredient Codeine Product Portfolios and Specifications
13.7.3 Cipla Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Cipla Main Business Overview
13.7.5 Cipla Latest Developments
13.8 Hikma
13.8.1 Hikma Company Information
13.8.2 Hikma Multi-ingredient Codeine Product Portfolios and Specifications
13.8.3 Hikma Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Hikma Main Business Overview
13.8.5 Hikma Latest Developments
13.9 Pharmaceutical Associates
13.9.1 Pharmaceutical Associates Company Information
13.9.2 Pharmaceutical Associates Multi-ingredient Codeine Product Portfolios and Specifications
13.9.3 Pharmaceutical Associates Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Pharmaceutical Associates Main Business Overview
13.9.5 Pharmaceutical Associates Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Multi-ingredient Codeine Product Portfolios and Specifications
13.10.3 Novartis Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Apotex
13.11.1 Apotex Company Information
13.11.2 Apotex Multi-ingredient Codeine Product Portfolios and Specifications
13.11.3 Apotex Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Apotex Main Business Overview
13.11.5 Apotex Latest Developments
13.12 Mylan
13.12.1 Mylan Company Information
13.12.2 Mylan Multi-ingredient Codeine Product Portfolios and Specifications
13.12.3 Mylan Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Mylan Main Business Overview
13.12.5 Mylan Latest Developments
13.13 Aristo Pharma GmbH
13.13.1 Aristo Pharma GmbH Company Information
13.13.2 Aristo Pharma GmbH Multi-ingredient Codeine Product Portfolios and Specifications
13.13.3 Aristo Pharma GmbH Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Aristo Pharma GmbH Main Business Overview
13.13.5 Aristo Pharma GmbH Latest Developments
13.14 Lannett Company
13.14.1 Lannett Company Company Information
13.14.2 Lannett Company Multi-ingredient Codeine Product Portfolios and Specifications
13.14.3 Lannett Company Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Lannett Company Main Business Overview
13.14.5 Lannett Company Latest Developments
13.15 Laboratoire Riva
13.15.1 Laboratoire Riva Company Information
13.15.2 Laboratoire Riva Multi-ingredient Codeine Product Portfolios and Specifications
13.15.3 Laboratoire Riva Multi-ingredient Codeine Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Laboratoire Riva Main Business Overview
13.15.5 Laboratoire Riva Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂